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Sepsis
• Sepsis is a potentially fatal whole-body inflammatory 
reaction caused by severe infection 
• 35% mortality
• > 7 million deaths/year
• The cost of Sepsis is high, and rising. In 2008, > €10 
billion were spent on hospitalizations for Sepsis in both 
Europe and the USA. 
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• During the course of a Sepsis infection, the blood of 
patients will contain specific biomarkers.
• In The RAIS project, we will initially focus on the 
following Sepsis biomarkers:
Biomarker Comments
C-reactive protein Sepsis 170 to >200 µg/ml
Procalcitonin Sepsis >0.5 ng/ml
Interleukin-6 Sepsis >120 pg/ml
MR-pro-Adrenomedullin Sepsis >1.1 nmol/L
miRNA146a, miRNA223, 
miRNA15a, miRNA16
Sepsis Low fM range (broad 
range 0.1fM-pM)
Antimicrobial resistance 
mechanisms 
CTX-M-type betalactamase, 
CMY-type betalactamase, VIM-type 
carbapenemasa, OXA-48-type 
carbapenemasa, Penicillin binding 
protein 2a (PBP2a)
Bacteria Escherichia coli, Klebsiella
pneumoniae, Sthapylococcus aureus, 
Pseudomonas aeruginosa
Sepsis
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Cartridge
• The Sepsis biomarkers can be captured by specific 
receptors deposited on a transparent micro-array 
plate.
• A disposable cartridge combining the microarray plate 
and microfluidics will be used to bring the patient 
blood into contact with the specific receptors.
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Cartridge
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• Plasmonic nano-structures will be designed to 
facilitate the detection of Sepsis biomarkers in the 
micro-array reader, by enhancing the light interaction 
with the protein array.
Reader
• The RAIS platform will use an optical microarray 
reader based on interferometric lens-free microscopy 
and large-area CMOS image sensing.
• Thanks to the large field-of-view of the image sensor, 
potentially > 1 million targets can be probed at the 
same time, allowing high-throughput, rapid detection 
of many proteins or pathogenic microorganisms.
8
Reader
• Contrary to ELISA tests, the RAIS technology is 
based on a very high-sensitivity interferometric 
configuration, which means it can do without protein 
amplification  very short time to result
• The proposed system will have a very small form 
factor, be battery powered and manufacturing will 
cost around €1000, making it very suitable for 
point-of-care applications. 
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